Literature DB >> 3802834

Sample size determination in clinical trials with time-dependent rates of losses and noncompliance.

E Lakatos.   

Abstract

Sample size determination is an important part of planning for clinical trials. During the course of a typical clinical trial, people are lost because of competing risks, noncompliance, and the like. Event rates available to the trial designers usually do not take these losses into consideration so that adjustment of these rates is necessary for sample size calculation. This article presents a method of adjusting such rates in the presence of time-dependent rates of losses, noncompliance, and the like. Lag in the effectiveness of medication is also considered.

Entities:  

Mesh：

Year:  1986        PMID： 3802834     DOI： 10.1016/0197-2456(86)90047-4

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN： 0197-2456


  9 in total

1.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Global left atrial strain in the prediction of sinus rhythm maintenance after catheter ablation for atrial fibrillation.

Authors:  Hirohiko Motoki; Kazuaki Negishi; Kenya Kusunose; Zoran B Popović; Mandeep Bhargava; Oussama M Wazni; Walid I Saliba; Mina K Chung; Thomas H Marwick; Allan L Klein
Journal:  J Am Soc Echocardiogr       Date:  2014-09-23       Impact factor: 5.251

3.  Single-arm Phase II cancer survival trial designs.

Authors:  Jianrong Wu
Journal:  J Biopharm Stat       Date:  2015-06-22       Impact factor: 1.051

4.  Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure.

Authors:  Richard Steinacher; John T Parissis; Bernhard Strohmer; Jörg Eichinger; Dennis Rottlaender; Uta C Hoppe; Johann Altenberger
Journal:  Clin Res Cardiol       Date:  2012-03-07       Impact factor: 5.460

5.  Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.

Authors:  Catherine M Viscoli; Lawrence M Brass; Antonio Carolei; Robin Conwit; Gary A Ford; Karen L Furie; Mark Gorman; Peter D Guarino; Silvio E Inzucchi; Anne M Lovejoy; Mark W Parsons; Peter N Peduzzi; Peter A Ringleb; Gregory G Schwartz; J David Spence; David Tanne; Lawrence H Young; Walter N Kernan
Journal:  Am Heart J       Date:  2014-07-28       Impact factor: 4.749

6.  Combination Hemotherapy and Mortality Prevention (CHAMP) Study Rationale and Design.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-09       Impact factor: 2.300

7.  Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks.

Authors:  Qing Yang; Wing K Fung; Gang Li
Journal:  Stat Med       Date:  2017-12-27       Impact factor: 2.497

8.  Informative noncompliance in endpoint trials.

Authors:  Steven M Snapinn; Qi Jiang; Boris Iglewicz
Journal:  Curr Control Trials Cardiovasc Med       Date:  2004-07-03

9.  Cohort Multiple Randomised Controlled Trials (cmRCT) design: efficient but biased? A simulation study to evaluate the feasibility of the Cluster cmRCT design.

Authors:  Alexander Pate; Jane Candlish; Matthew Sperrin; Tjeerd Pieter Van Staa
Journal:  BMC Med Res Methodol       Date:  2016-08-26       Impact factor: 4.615
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.